Arrow-right Camera
The Spokesman-Review Newspaper

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Cloudy 32° Cloudy

Tag search results

Tags let us describe our content with keywords, making it easier to find what you're most interested in. Use the search box to look for tags, or explore our coverage with the lists below.

Family behind OxyContin attests to its role in opioid crisis

Two of the owners of the company that makes OxyContin acknowledged to a congressional committee on Thursday that the powerful prescription painkiller has played a role in the national opioid crisis but stopped short of apologizing or admitting wrongdoing.

Senate report: Opioid industry has paid advocacy groups $65M

A bipartisan congressional investigation released Wednesday found that key players in the nation’s opioid industry have spent $65 million since 1997 funding nonprofits that advocate treating pain with medications, a strategy intended to boost the sale of prescription painkillers.

Money promised to combat US overdose crisis sits unused

When it filed for bankruptcy last year, Purdue Pharma agreed to an innovative plan: It would make $200 million available immediately to help those those harmed by its signature painkiller, OxyContin, and ease the effects of the opioid crisis. More than a year later, with the crisis worsening, not a penny has been spent.

Judge will halt lawsuits against Purdue Pharma, its owners

A judge is pushing for a settlement of more than 2,600 lawsuits facing OxyContin maker Purdue Pharma with a decision Friday to pause litigation against the company and members of the wealthy Sackler family that owns the company.

Spokane City Council agrees to pursue legal action against manufacturers of opioid painkillers

Lawmakers asked the city’s legal team last year to explore litigation against the makers of OxyContin and other prescription painkillers, cited as the major source of the country’s opioid crisis. The contract with a Seattle law firm to pursue legal action follows a request by the City Council for city attorneys to take another look at joining in the wake of one of the manufacturers announcing a multibillion dollar settlement.

Purdue Pharma to stay in business as bankruptcy unfolds

A judge has cleared the way for OxyContin maker Purdue Pharma to stay in business while it pursues bankruptcy protection and settlement of more than 2,600 lawsuits filed over the opioid crisis. Purdue lawyers secured permission Tuesday for the company to maintain business as usual. That includes paying employees and vendors, supplying pills to distributors, and keeping current on taxes and insurance.

OxyContin maker, government attorneys in settlement talks

State attorneys general and lawyers representing local governments say they are in active settlement negotiations amid a report that OxyContin maker Purdue Pharma has offered to settle for $10 billion to $12 billion.

California sues opioid maker Purdue Pharma

California on Monday became the latest state to sue the pharmaceutical company behind the painkiller OxyContin, alleging it falsely promoted the drug as not addictive even as it emerged as one of the most widely abused in the U.S.

Maker of OxyContin reaches $270M settlement in Oklahoma

The maker of OxyContin and the company’s controlling family agreed Tuesday to pay a groundbreaking $270 million to Oklahoma to settle allegations they helped create the nation’s deadly opioid crisis with their aggressive marketing of the powerful painkiller.

OxyContin maker: Lawsuit distorts facts, scapegoats company

OxyContin maker Purdue Pharma is asking a Massachusetts court to throw out a lawsuit filed by the state’s attorney general that accuses the company, its owners and top executives of deceiving patients and doctors about the risks of opioids.

Montana seeks marketing injunction against OxyContin maker

The state of Montana is seeking a preliminary injunction to prevent the maker of the powerful painkiller OxyContin from marketing opioids to Montana prescribers, seeking to put the force of a court order behind Purdue Pharma’s recent promise to end such marketing nationwide.